Serotonin

Corrupt Practices | Psychiatry

Relapse Producing Experiments – a Partial Bibliography
October 26, 2006May 3, 2016

<spanstyle=’font-size:11.0pt;font-family:Arial’>FEDERALLY-FUNDED RELAPSE PRODUCING EXPERIMENTS in PSYCHIATRY: DRUG WASHOUT / CHEMICAL PROVOCATION<spanstyle=’font-size:11.0pt;font-family:Arial’> <spanstyle=’font-size:11.0pt;font-family:Arial’>A PARTIAL BIBLIOGRAPHY (Jan 2000) <spanstyle=’font-size:11.0pt;font-family:Arial’>By VERA HASSNER SHARAV Experiments such as those listed below have no diagnostic or therapeutic purpose: They are conducted often on disabled veterans to test speculative, unproven theories. National Institute of Mental Health:<spanstyle=’font-size:11.0pt;font-family:Arial’>…

Read More Relapse Producing Experiments – a Partial Bibliography
Miscellaneous

Anatomy of an Epidemic: Psychiatric Drugs and the Astonishing Rise of Mental Illness in America – Whitaker
October 26, 2006November 21, 2014

Anatomy of an Epidemic: Psychiatric Drugs and the Astonishing Rise of Mental Illness in America by Robert Whitaker, Ethical Human Psychology and Psychiatry, Volume 7, Number I , Spring 2005 Mon, 29 Aug 2005 Some uncritical promoters of psychiatry and its current biological treatment paradigm have declared that the introduction…

Read More Anatomy of an Epidemic: Psychiatric Drugs and the Astonishing Rise of Mental Illness in America – Whitaker
Miscellaneous

Statin-Cholesterol Guidelines–Industry influenced?
October 26, 2006November 21, 2014

Statin-Cholesterol Guidelines–Industry influenced? Wed, 14 Jul 2004 Scientific journal editors are scrambling about how to react to bad publicity emanating from public disclosure that the scientific reports they have published are likely to be biased because the authors’ had financial ties to the companies whose drugs / devices they report…

Read More Statin-Cholesterol Guidelines–Industry influenced?
Miscellaneous

FDA Bad Faith – Daniel Troy’s pre-emption defense – Nat’l Law Journal
October 26, 2006November 21, 2014

FDA Bad Faith – Daniel Troy’s pre-emption defense – Nat’l Law Journal Fri, 26 Mar 2004 Federal regulations require drug label warnings if there is “reasonable evidence” of a link between adverse effects and drug action. An article in the National Law Journal shows how s FDA’s chief counsel, Daniel…

Read More FDA Bad Faith – Daniel Troy’s pre-emption defense – Nat’l Law Journal
Miscellaneous

Commonly recommended Treatments found Worthless
October 26, 2006November 21, 2014

Commonly recommended Treatments found Worthless Wed, 19 Mar 2003 Independent analyses of the clinical studies upon which widely recommended drug treatments have been based, have now been found to be fatally faulty, and the drugs are deemed worthless. An analysis of 83 studies found that drugs used to treat 90,000…

Read More Commonly recommended Treatments found Worthless
Miscellaneous

Are we all going mad, or are the experts crazy? / Are psychiatric drugs an assault on the human condition?
October 26, 2006November 21, 2014

Are we all going mad, or are the experts crazy? / Are psychiatric drugs an assault on the human condition? Fri, 19 Aug 2005 Below, two companion pieces: An Op Ed in the Los Angeles Times, by Stuart Kirk, a professor of social welfare at UCLA, addresses psychiatry’s conundum: the…

Read More Are we all going mad, or are the experts crazy? / Are psychiatric drugs an assault on the human condition?
Miscellaneous

Pfizer Admits Guilt in Promotion of Neurontin–Agrees to Pay $430 Million
October 26, 2006November 21, 2014

Pfizer Admits Guilt in Promotion of Neurontin–Agrees to Pay $430 Million Sun, 16 May 2004 A lawsuit initiated by Dr. David Franklin, a whistleblower, has been settled: Pfizer pleaded guilty to criminal fraud in the promotion of Neurontin, and agreed to pay $430 million. This case is but an example…

Read More Pfizer Admits Guilt in Promotion of Neurontin–Agrees to Pay $430 Million
Miscellaneous

Antidepressant Controversy: Media Conflicts of Interest – New York Times
October 26, 2006November 21, 2014

Antidepressant Controversy: Media Conflicts of Interest – New York Times Thu, 25 Mar 2004 FDA’s advisory warning about antidepressant drugs received wide press coverage nationally. But few in the national media mentioned conflicts of interest as the obstacle to disclosure of evidence showing these drugs’ adverse effects. Among the few…

Read More Antidepressant Controversy: Media Conflicts of Interest – New York Times
Conflict of Interest

Conflicts of Interest Taint UK Gov panel investigating SSRI
October 26, 2006May 3, 2016

Conflicts of Interest Taint UK Gov panel investigating SSRI Wed, 19 Mar 2003 An article from the UK Guardian sheds light on how the credibility of an expert investigative government appointed committee is corrupted by financial conflicts of interest. Mounting complaints from patients and the UK watchdog organization, Social Audit,…

Read More Conflicts of Interest Taint UK Gov panel investigating SSRI
Miscellaneous

NIMH Offers Grants to Study SSRI relation to Suicidality – FDA to Examine SSRI- Suicide in Adults
October 26, 2006November 21, 2014

NIMH Offers Grants to Study SSRI relation to Suicidality_FDA to Examine SSRI- Suicide in Adults Mon, 14 Nov 2005 A fifteen year struggle by critics of the drug-centered treatment paradigm in psychiatry is being indirectly validated both by the FDA and the National Institute of Mental Health who are addressing…

Read More NIMH Offers Grants to Study SSRI relation to Suicidality – FDA to Examine SSRI- Suicide in Adults
Miscellaneous

Article
October 26, 2006November 21, 2014

The Evidence base: rock of certainty or shifting sands? – BMJ Wed, 5 May 2004 Dr. John Dewhurst, has written an extraordinary article from his first-hand experience as a pharmaceutical company physician who discovered the disparity that exists between the claimed and actual evidence of drug effectiveness–and the reality-based severe,…

Read More Article
Miscellaneous

FDA Approves Lilly’s Cymbalta for Depression Despite Risk of Suicide
October 26, 2006November 21, 2014

FDA Approves Lilly’s Cymbalta for Depression Despite Risk of Suicide Wed, 4 Aug 2004 In a display of arrogance and defiance–in the midst of federal investigations into the marketing of antidepressants–the FDA has approved Eli Lilly’s antidepression drug, Cymbalta (duloxetine). Lilly’s press release announced: “Cymbalta, a balanced and potent reuptake…

Read More FDA Approves Lilly’s Cymbalta for Depression Despite Risk of Suicide